Wallenberg Neuroscience Center, Department of Experimental Medical Sciences, Lund University, Lund 221 84, Sweden.
Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3213-9. doi: 10.1073/pnas.1200575109. Epub 2012 Feb 6.
We used in vivo amperometry to monitor changes in synaptic dopamine (DA) release in the striatum induced by overexpression of human wild-type α-synuclein in nigral DA neurons, induced by injection of an adeno-associated virus type 6 (AAV6)-α-synuclein vector unilaterally into the substantia nigra in adult rats. Impairments in DA release evolved in parallel with the development of degenerative changes in the nigrostriatal axons and terminals. The earliest change, seen 10 d after vector injection, was a marked, ≈50%, reduction in DA reuptake, consistent with an early dysfunction of the DA transporter that developed before any overt signs of axonal damage. At 3 wk, when the first signs of axonal damage were observed, the amount of DA released after a KCl pulse was reduced by 70-80%, and peak DA concentration was delayed, indicating an impaired release mechanism. At later time points, 8-16 wk, overall striatal innervation density was reduced by 60-80% and accompanied by abundant signs of axonal damage in the form of α-synuclein aggregates, axonal swellings, and dystrophic axonal profiles. At this stage DA release and reuptake were profoundly reduced, by 80-90%. The early changes in synaptic DA release induced by overexpression of human α-synuclein support the idea that early predegenerative changes in the handling of DA may initiate, and drive, a progressive degenerative process that hits the axons and terminals first. Synaptic dysfunction and axonopathy would thus be the hallmark of presymptomatic and early-stage Parkinson disease, followed by neuronal degeneration and cell loss, characteristic of more advanced stages of the disease.
我们使用活体安培法监测在成年大鼠单侧纹状体注射腺相关病毒 6 (AAV6)-α-突触核蛋白载体后,黑质多巴胺神经元中过表达人野生型 α-突触核蛋白引起的纹状体突触多巴胺 (DA) 释放的变化。DA 释放的损伤与黑质纹状体轴突和末梢的退行性变化同时发展。最早的变化发生在载体注射后 10 天,即 DA 再摄取明显减少约 50%,这与多巴胺转运体的早期功能障碍一致,该功能障碍在任何明显的轴突损伤迹象之前发生。在 3 周时,当观察到轴突损伤的第一个迹象时,KCl 脉冲后释放的 DA 减少了 70-80%,并且峰值 DA 浓度延迟,表明释放机制受损。在稍后的时间点,8-16 周,纹状体的整体神经支配密度降低了 60-80%,并伴有大量的轴突损伤迹象,如 α-突触核蛋白聚集、轴突肿胀和退行性轴突形态。在这个阶段,DA 释放和再摄取减少了 80-90%。人 α-突触核蛋白过表达诱导的突触 DA 释放的早期变化支持这样一种观点,即 DA 处理的早期退行性前变化可能引发并驱动首先影响轴突和末梢的进行性退行性过程。因此,突触功能障碍和轴突病将成为前驱期和早期帕金森病的标志,随后是神经元变性和细胞丢失,这是疾病更晚期的特征。